Trends in antipsychotic prescribing practices in an urban community mental health clinic

Australasian Psychiatry

Volumn 18, Issue 3, 2010, Pages 238-241

  Monshat, Kaveh ^a,c   Carty, Bridget ^b   Olver, James ^a   Castle, David ^a   Bosanac, Peter ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c St Vincent's Health   (Australia)

Author keywords

Antipsychotics; Community psychiatry; Outpatients; Prescribing

Indexed keywords

CLOZAPINE; HYPNOTIC AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; CLINICAL PRACTICE; COMMUNITY MENTAL HEALTH CENTER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; MAJOR CLINICAL STUDY; PATIENT CARE; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT INDICATION;

ADMINISTRATION, ORAL; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; CASE MANAGEMENT; COMMUNITY MENTAL HEALTH CENTERS; CROSS-SECTIONAL STUDIES; DELAYED-ACTION PREPARATIONS; DIBENZOTHIAZEPINES; DRUG UTILIZATION; HUMANS; HYPNOTICS AND SEDATIVES; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; URBAN POPULATION; VICTORIA;

EID: 77952872931     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.3109/10398561003681327     Document Type: Article

References (21)

1. Mond J, Morice R, Owen C, Korten A. Use of antipsychotic medications in Australia between July 1995 and December 2001. Australian and New Zealand Journal of Psychiatry 2003; 37 : 55-61.
2. Jablensky A, McGrath J, Herrman H et al. N ational Survey of Mental Health and Wellbeing. Report 4. People Living with Psychotic Illness: an Australian Study . Canberra: Commonwealth Department of Health and Aged Care, 1999.
3. Keks NA, Altson K, Hope J et al . Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Australian and New Zealand Journal of Psychiatry 1999; 33 : 896-901.
4. Callaly T, Trauer T. Patterns of use of antipsychotic medication in a regional community mental health service. Australasian Psychiatry 2000; 8 : 220-224.
5. Humberstone V, Wheeler A, Lambert T. An audit of outpatient antipsychotic usage in the three health sectors of Auckland, New Zealand. Australian and New Zealand Journal of Psychiatry 2004; 38 : 240-245.
6. Wheeler A. Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions. New Zealand Medical Journal 2006; 119 .
7. RANZCP Clinical Practice Guidelines Team. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39 : 1-30.
8. Lambert TJR, Castle DJ. Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia 2003; 178 : S57-S61.
9. Lewis S, Lieberman J. CATIE and CUtLASS: Can we handle the truth? B ritish Journal of Psychiatry 2008; 192 : 161-163.
10. Lambert TJR, Chapman LH, Bell S et al . Diabetes, psychotic disorders and antipsychotic therapy: A consensus statement. Medical Journal of Australia 2004; 181 : 544-548.
11. Hamann J, Leucht S, Kissling W. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003; 36 : 18-26.
12. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A rchives of General Psychiatry 2006; 63 : 1069-1072.
13. Cook PE, Goldberg JO, Van Lieshout RJ. Benefi ts of switching from typical to atypical antipsychotic medications: A longitudinal study in a community-based setting. Canadian Journal of Psychiatry 2002; 47 : 870-874.
14. Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: A 2-year comparison. Journal of Clinical Psychiatry 2003; 64 : 673-679.
15. Baune BT. New developments in the management of major depressive disorder and generalized anxiety disorder: Role of quetiapine. Neuropsychiatric Disease and Treatment 2008; 4 : 1181-1192.
16. Davis JM, Chen N, Glick ID. A meta-analysis of the effi cacy of second-generation antipsychotics. Archives of General Psychiatry 2003; 60 : 553-564.
17. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry 2002; 159 : 1005-1010. (Pubitemid 34586947)
18. Fleurence RL, Chatterton ML, Dixon JM, Rajagopalan K. Economic outcomes associated with atypical antipsychotics in bipolar disorder: A systematic review. Primary Care Companion to the Journal of Clinical Psychiatry 2007; 9 : 419-428.
19. Correll CU, Frederickson AM, Kane JM, Manu P. Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disorders 2008; 10 : 788-797.
20. Rosenberg RP. Sleep maintenance insomnia: Strengths and weaknesses of current pharmacologic therapies. Annals of Clinical Psychiatry 2006; 18 : 49-56.
21. Olson LG. Hypnotic hazards: Adverse effects of zolpidem and other z-drugs. A ustralian Prescriber 2008; 31 : 146-149.